GeneDx Holdings Corp. leverages genomics leadership with robust growth, despite recent stock challenges. Click for more on ...

OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a ...

These included the sale of its BioReference laboratory testing businesses, which focused on oncology and oncology-related ...

OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, ...

OPKO Health is witnessing a negative estimate revision trend for 2025. In the past 60 days, the Zacks Consensus Estimate for its loss has widened from 25 cents to 30 cents per share.

OPKO Health, Inc. (NASDAQ:OPK) has been a large holding of mine for years. There is a love/hate relationship with the stock (definitely more heavily leaning towards the hate).

Opko Health , Inc. (NASDAQ: OPK), a pharmaceutical company with a market capitalization of $1.07 billion, disclosed in a recent SEC filing that its Compensation Committee has made significant ...

OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company. The company is engaged in discovering, developing, commercializing and expertise ...